Synthesis and In Vitro Cytotoxicity of 1,3-Dioxoindan-2-Carboxylic Acid Arylamides
![]() ![]() |
Jung, Jae-Kyung
(College of Pharmacy, Chungbuk National University)
Ryu, Jin-Hyeong (College of Pharmacy, Chungbuk National University) Yang, Sung-Il (College of Medicine, Kunkuk University) Cho, Jung-Sook (College of Medicine, Dongguk University) Lee , Hee-Soon (College of Pharmacy, Chungbuk National University) |
1 | Cortes, F. and Pinero, J., Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemather. Pharmacal., 34, 411-415(1994) DOI ScienceOn |
2 | Dittrich, C., Coudert, B., Paz-Ares, L., Caponigro, F., Salzberg, M., Gamucci,T., Paoletti, X., Hermans,C., and Lacombe, D., Fumoleau P. and on behalf of the European Organization for Research and Treatment of CancerEarly Clinical Studies Group/New Drug Development Programme(EORTC-ECSG/ NDDP), Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. European J. Cancer, 39,330-334 (2003) DOI ScienceOn |
3 | Lee, H., Lee, J., Hong, S-. S., Yang, S-. I., Jung, S.-H., Jahng, Y., and Cho, J., Synthesis and in vitro cytotoxicity of 2-alkylaminosubstituted quinoline derivatives. Arch. Pharm. Res., 23, 450-454 (2000) DOI ScienceOn |
4 | Skehan, P., Storeng, R., Scudiero, D, Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990) DOI PUBMED |
5 | Bonner, J. A. and Kozelsky, T. F., The significance of the sequence of administration of topotecan and etoposide. Cancer Chemather. Pharmacal., 39, 109-112 (1996) DOI ScienceOn |
6 | Minderman, H., Wrzosek, C., Cao, S. S., Utsugi,T., Kobunai, T., Yamada, Y, and Rustum, Y. M., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemather. Pharmacal., 45, 78-84 (2000)and references cited therein. DOI ScienceOn |
7 | Lee, H., Lee, J., and Yang, S-I., Synthesis and in vitro cytotoxicity of 4-alkyl- or 4-arylaminosubstituted cyclopenta [c]quinoline derivatives. Arch. Pharm. Res., 24, 385-389 (2001) DOI ScienceOn |
8 | Baguley, B. C., Zhuang, L., and Marshall, E. M., Experimental solid tumor activity of N-[2-(dimethylamino)-ethyl] acridine-4-carboxamide. Cancer Chemather. Pharmacal., 36, 244-248 (1995). DOI ScienceOn |
9 | Kaslow, C. E. and Sommer, N. B., SubstitutedLepidines. J. Am. Chem. Soc., 68, 644-646(1946) DOI |
10 | Aoyagi, Y., Kobunai, T., Utsugi, T., Oh-hara, T., and Yamada, Y., In vitro antitumor activity of TAS-103, a novel quinoline derivative that targets topoisomerases I and II. Jpn. J. Cancer Res., 90, 578-587, (1999) and references cited therein DOI PUBMED |
11 | Atwell, G. J., Rewcastle, G. W., Baguley, B. C., and Denny, W. A., Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem., 30, 664-669(1987). DOI PUBMED |
12 | Potts, K. T., Bhattachaarjee, D., and Walsh E. B., Cycloaddition routes to azaanthraquinone derivatives. 1. use of azadienophiles. J. Org. Chem., 51, 2011-2021 (1986) DOI |
![]() |